Safety and Feasibility of Induction Immunosuppression When Driveline Infection Is an Indication for Cardiac Transplantation

Thoracic and Cardiovascular Surgeon

Volumn 63, Issue 8, 2015, Pages 675-683

  Bhatia, Nirmanmoh ^a   Voelkel, Anthony J ^b   Hussain, Zeeshan ^c   Sharma, Umesh C ^d   Slaughter, Mark S ^c   Birks, Emma J ^c   McCants, Kelly C ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c University of Louisville School of Medicine   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

driveline infection; induction immunosuppression; orthotopic heart transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; ASPERGILLOSIS; BACTERIAL PNEUMONIA; CARDIAC GRAFT REJECTION; CARDIOVASCULAR MORTALITY; CELLULITIS; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRIVELINE INFECTION; DRUG SAFETY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI INFECTION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HERPES ZOSTER; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LEFT VENTRICULAR ASSIST DEVICE; LENGTH OF STAY; LUNG MYCOSIS; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OUTCOME ASSESSMENT; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; PULMONARY CANDIDIASIS; URINARY TRACT INFECTION; ADVERSE EFFECTS; AGED; FACTUAL DATABASE; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; KAPLAN MEIER METHOD; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROSTHESIS DESIGN; PROSTHESIS-RELATED INFECTIONS; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; DATABASES, FACTUAL; FEASIBILITY STUDIES; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; MALE; MIDDLE AGED; PROSTHESIS DESIGN; PROSTHESIS-RELATED INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84949088019     PISSN: 01716425     EISSN: 14391902     Source Type: Journal    
DOI: 10.1055/s-0035-1564449     Document Type: Article

References (34)

1. Shapiro R., Young J. B., Milford E. L., Trotter J. F., Bustami R. T., Leichtman A. B. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant: 2005; 5 (4, Pt 2): 874 886
2. Hawksworth J. S., Leeser D., Jindal R. M., Falta E., Tadaki D., Elster E. A. New directions for induction immunosuppression strategy in solid organ transplantation. Am J Surg: 2009; 197 4 515 524
3. Rosenberg P. B., Vriesendorp A. E., Drazner M. H., et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant: 2005; 24 9 1327 1331
4. Cantarovich M., Giannetti N., Barkun J., Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation: 2004; 78 5 779 781
5. Yamani M. H., Taylor D. O., Czerr J., et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant: 2008; 22 1 76 81
6. Lund L. H., Edwards L. B., Kucheryavaya A. Y., et al. International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report-2013; focus theme: age. J Heart Lung Transplant: 2013; 32 10 951 964
7. Higgins R., Kirklin J. K., Brown R. N., et al. Cardiac Transplant Research Database (CTRD). To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Lung Transplant: 2005; 24 4 392 400
8. Uber P. A., Mehra M. R. Induction therapy in heart transplantation: is there a role? J Heart Lung Transplant: 2007; 26 3 205 209
9. Hershberger R. E., Starling R. C., Eisen H. J., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med: 2005; 352 26 2705 2713
10. Kirklin J. K., Naftel D. C., Pagani F. D., et al. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant: 2014; 33 6 555 564
11. Go A. S., Mozaffarian D., Roger V. L., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation: 2014; 129 3 399 410
12. Miller L. W., Pagani F. D., Russell S. D., et al. HeartMate II Clinical Investigators. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med: 2007; 357 9 885 896
13. Sharma V., Deo S. V., Stulak J. M., et al. Driveline infections in left ventricular assist devices: implications for destination therapy. Ann Thorac Surg: 2012; 94 5 1381 1386
14. Zierer A., Melby S. J., Voeller R. K., et al. Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. Ann Thorac Surg: 2007; 84 2 515 520
15. Poston R. S., Husain S., Sorce D., et al. LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection. J Heart Lung Transplant: 2003; 22 8 914 921
16. Hannan M. M., Husain S., Mattner F., et al. International Society for Heart and Lung Transplantation. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant: 2011; 30 4 375 384
17. Simon D., Fischer S., Grossman A., et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis: 2005; 40 8 1108 1115
18. Raymond A. L., Kfoury A. G., Bishop C. J., et al. Obesity and left ventricular assist device driveline exit site infection. ASAIO J: 2010; 56 1 57 60
19. Aliabadi A., Grömmer M., Zuckermann A. Is induction therapy still needed in heart transplantation? Curr Opin Organ Transplant: 2011; 16 5 536 542
20. Smart F. W., Naftel D. C., Costanzo M. R., et al. Risk factors for early, cumulative, and fatal infections after heart transplantation: a multiinstitutional study. J Heart Lung Transplant: 1996; 15 4 329 341
21. Aziz T., el-Gamel A., Krysiak P., et al. Risk factors for early mortality, acute rejection, and factors affecting first-year survival after heart transplantation. Transplant Proc: 1998; 30 5 1912 1914
22. Kubo S. H., Naftel D. C., Mills R. M. Jr., et al. Cardiac Transplant Research Database Group. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. J Heart Lung Transplant: 1995; 14 3 409 418
23. Al Aly Z., Abbas S., Moore E., Diallo O., Hauptman P. J., Bastani B. The natural history of renal function following orthotopic heart transplant. Clin Transplant: 2005; 19 5 683 689
24. Segovia J., Rodríguez-Lambert J. L., Crespo-Leiro M. G., et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation: 2006; 81 11 1542 1548
25. Moller C. H., Gustafsson F., Gluud C., Steinbrüchel D. A. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials. J Heart Lung Transplant: 2008; 27 8 835 842
26. Schulman A. R., Martens T. P., Christos P. J., et al. Comparisons of infection complications between continuous flow and pulsatile flow left ventricular assist devices. J Thorac Cardiovasc Surg: 2007; 133 3 841 842
27. Gordon R. J., Quagliarello B., Lowy F. D. Ventricular assist device-related infections. Lancet Infect Dis: 2006; 6 7 426 437
28. Arrecubieta C., Asai T., Bayern M., et al. The role of Staphylococcus aureus adhesins in the pathogenesis of ventricular assist device-related infections. J Infect Dis: 2006; 193 8 1109 1119
29. Aslam S., Hernandez M., Thornby J., Zeluff B., Darouiche R. O. Risk factors and outcomes of fungal ventricular-assist device infections. Clin Infect Dis: 2010; 50 5 664 671
30. Gómez-Moreno S., Lage E., Jiménez-Jambrina M., et al. Infections in cardiac transplant recipients: clinical and microbiological characteristics and consequences. Transplant Proc: 2006; 38 8 2555 2557
31. González-Vílchez F., de Prada J. A., Exposito V., et al. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant: 2008; 27 10 1135 1141
32. Schulman A. R., Martens T. P., Russo M. J., et al. Effect of left ventricular assist device infection on post-transplant outcomes. J Heart Lung Transplant: 2009; 28 3 237 242
33. Ankersmit H. J., Tugulea S., Spanier T., et al. Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet: 1999; 354 9178 550 555
34. Bhatia N., Voelkel A., Sharma U., Birks E., McCants K. Safety and outcomes of induction immunosuppression for cardiac transplantation in patients with active driveline infection. J Am Coll Cardiol: 2014; 63 12 A857